Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.

ABSTRACT:

Background

Although alopecia areata (AA) greatly impacts patients' quality of life (QoL), there is no adequate validation of AA-targeted QoL surveys in clinical trials, hindering sufficient representation of patient-reported outcomes.

Objectives

Better understanding of patient-reported outcomes may guide treatment goals and future clinical trials.

Methods

In a recent randomized controlled trial testing dupilumab in AA, patients were administered the Alopecia Areata Quality of Life Index (AA-QLI) and the Alopecia Areata Symptom Impact Scale (AASIS) surveys, specifically evaluating QoL in patients with AA. An in-depth analysis was performed to assess the utility of these questionnaires in this patient population, both at baseline and after treatment, and to determine a

SUBMITTER: Renert-Yuval Y 

PROVIDER: S-EPMC10291970 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature